[go: up one dir, main page]

MA40224A - Anticorps se liant aux protofibrilles ass améliorés - Google Patents

Anticorps se liant aux protofibrilles ass améliorés

Info

Publication number
MA40224A
MA40224A MA040224A MA40224A MA40224A MA 40224 A MA40224 A MA 40224A MA 040224 A MA040224 A MA 040224A MA 40224 A MA40224 A MA 40224A MA 40224 A MA40224 A MA 40224A
Authority
MA
Morocco
Prior art keywords
protofibrilles
ass
enhanced
antibodies binding
antibodies
Prior art date
Application number
MA040224A
Other languages
English (en)
Other versions
MA40224B1 (fr
Inventor
Hanna Laudon
Charlotte Nerelius
Jessica Sigvardson
Original Assignee
Bioarctic Ab
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab, Eisai R&D Man Co Ltd filed Critical Bioarctic Ab
Publication of MA40224A publication Critical patent/MA40224A/fr
Publication of MA40224B1 publication Critical patent/MA40224B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne le peptide bêta amyloïde (aβ) et, plus spécifiquement, des anticorps se liant à des protofibrilles aβ et leur utilisation à des fins thérapeutiques et/ou pour le traitement prophylactique de la maladie d'alzheimer et d'autres troubles associés à l'agrégation des protéines aβ. En outre, l'invention peut se rapporter au diagnostic de telles maladies, ainsi qu'au suivi de la progression de la maladie grâce à l'utilisation des anticorps de l'invention. En outre, l'invention peut se rapporter à un usage vétérinaire des anticorps de l'invention.
MA40224A 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés MA40224B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022952P 2014-07-10 2014-07-10
PCT/EP2015/065633 WO2016005466A2 (fr) 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés

Publications (2)

Publication Number Publication Date
MA40224A true MA40224A (fr) 2017-05-17
MA40224B1 MA40224B1 (fr) 2021-05-31

Family

ID=53673920

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053887A MA53887A (fr) 2014-07-10 2015-07-08 Anticorps à liaison protofibrille a-bêta améliorée
MA40224A MA40224B1 (fr) 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053887A MA53887A (fr) 2014-07-10 2015-07-08 Anticorps à liaison protofibrille a-bêta améliorée

Country Status (34)

Country Link
US (1) US9573994B2 (fr)
EP (2) EP3166970B1 (fr)
JP (1) JP6628786B2 (fr)
KR (2) KR102763164B1 (fr)
CN (2) CN112390881B (fr)
AR (1) AR101130A1 (fr)
AU (1) AU2015286707B2 (fr)
CA (1) CA2951990C (fr)
CL (1) CL2017000053A1 (fr)
CO (1) CO2017000346A2 (fr)
CY (1) CY1124563T1 (fr)
DK (1) DK3166970T3 (fr)
ES (1) ES2865112T3 (fr)
HR (1) HRP20210680T1 (fr)
HU (1) HUE053809T2 (fr)
IL (2) IL282823B2 (fr)
JO (1) JO3537B1 (fr)
LT (1) LT3166970T (fr)
MA (2) MA53887A (fr)
MX (1) MX379241B (fr)
MY (1) MY184890A (fr)
PE (1) PE20170768A1 (fr)
PH (1) PH12017500032B1 (fr)
PL (1) PL3166970T3 (fr)
PT (1) PT3166970T (fr)
RS (1) RS61717B1 (fr)
RU (1) RU2700104C2 (fr)
SG (1) SG11201610734RA (fr)
SI (1) SI3166970T1 (fr)
SM (1) SMT202100263T1 (fr)
TW (1) TWI678376B (fr)
UA (1) UA121550C2 (fr)
WO (1) WO2016005466A2 (fr)
ZA (1) ZA201706272B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
AU2017297804A1 (en) * 2016-07-14 2019-01-24 Bioarctic Ab Brain delivery protein
IL316169A (en) * 2016-10-27 2024-12-01 Eisai R&D Man Co Ltd Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
BR112020015479A2 (pt) * 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos
CA3107370A1 (fr) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methodes de traitement et de prevention de la maladie d'alzheimer
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
WO2023283650A1 (fr) 2021-07-09 2023-01-12 Eisai R&D Management Co., Ltd. Biomarqueurs pour le traitement de la maladie d'alzheimer
WO2023034230A1 (fr) 2021-08-30 2023-03-09 Eisai R&D Mangement Co., Ltd. Formulations sous-cutanées d'anticorps protofibrille anti-abêta et leurs méthodes d'utilisation
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
CN114578066B (zh) * 2022-05-07 2022-08-19 北京第一生物化学药业有限公司 检测β-淀粉样蛋白的产品和方法
WO2024155876A1 (fr) 2023-01-20 2024-07-25 Mabwell Therapeutics, Inc. ANTICORPS ANTI-PROTOFIBRILLE/OLIGOMÈRE β AMYLOÏDE ET LEURS UTILISATIONS

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US6174916B1 (en) 1990-04-27 2001-01-16 Milkhaus Laboratory, Ltd. Methods for treating herpes virus infections
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE69426571T2 (de) 1993-10-27 2001-08-09 Elan Pharm Inc TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
JP3064013B2 (ja) 1994-05-25 2000-07-12 ジョン マクマイケル， 斑形成疾患の治療のための方法及び材料
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2214247C (fr) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
WO1997041856A1 (fr) 1996-05-08 1997-11-13 Massachusetts Institute Of Technology LIGANDS ORGANOMETALLIQUES POUR LA LOCALISATION ET LA QUANTIFICATION D'AMYLOIDE IN VIVO ET $i(IN VITRO)
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20060178302A1 (en) 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE1033998T1 (de) 1997-12-03 2001-05-23 Brigham And Women's Hospital, Boston Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
AU2486900A (en) 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
WO2000071671A2 (fr) 1999-05-26 2000-11-30 New York University Nouveaux genes mutants dans la demence familiale britannique et la demence familiale danoise
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001006989A2 (fr) 1999-07-27 2001-02-01 Abgenix, Inc. Procedes et compositions permettant d'inhiber l'accumulation des polypeptides associee aux troubles neurologiques
EP1571158B1 (fr) 1999-08-04 2009-10-14 University Of Southern California Assemblage de protéine amyloide beta globulaire et ses utilisations
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU7487301A (en) 2000-05-22 2001-12-03 Univ New York Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20030187011A1 (en) 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
NZ536064A (en) 2002-04-19 2008-06-30 Univ Toronto Immunological methods and compositions for the treatment of alzheimer's disease
US20040049134A1 (en) 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
EP1578361B1 (fr) 2002-09-12 2011-04-20 The Regents of The University of California Immunogenes et anticorps correspondant specifiques pour des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides constitues par des proteines de sequences differentes
AU2003279728B2 (en) 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
AU2003285151A1 (en) 2002-11-04 2004-06-07 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005011599A2 (fr) 2003-08-01 2005-02-10 Northwestern University Anticorps specifiques des oligomeres a proteines beta amyloides toxiques
WO2005019828A1 (fr) 2003-08-20 2005-03-03 Amorfix Life Sciences Ltd. Dosage de protection d'epitope et procede de detection de conformations proteiques
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AU2005269940A1 (en) 2004-07-02 2006-02-09 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta)
US20060079447A1 (en) * 2004-10-08 2006-04-13 Wetzel Ronald B Stabilized A-beta protofibrillar aggregates
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006055178A2 (fr) * 2004-10-25 2006-05-26 Merck & Co., Inc. Anticorps anti-addl et leurs utilisations
WO2006066233A1 (fr) 2004-12-15 2006-06-22 Neuralab Limited Essai d'immunoprecipitation permettant de predire l'efficacite in vivo d'anticorps anti-proteine beta-amyloide
WO2006083533A2 (fr) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
US7741448B2 (en) 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
TW200726482A (en) 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
EP1940466B1 (fr) 2005-10-21 2012-11-28 Merck Sharp & Dohme Corp. Anticorps monoclonaux anti-addl et leur utilisation
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
UA100672C2 (en) * 2006-07-14 2013-01-25 Ас Иммуне Са HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN
CN101516911B (zh) * 2006-07-14 2016-11-16 Ac免疫有限公司 针对淀粉状蛋白β的人源化抗体
CN101611054B (zh) * 2006-10-02 2013-12-25 Ac免疫有限公司 针对淀粉状蛋白β的人源化抗体
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
US8975377B2 (en) * 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ME01026B (fr) * 2007-11-16 2012-10-20 Univ Rockefeller Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
AU2010229994B2 (en) 2009-03-25 2016-08-18 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
JP5692073B2 (ja) * 2009-08-07 2015-04-01 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
CA2806252C (fr) * 2010-07-29 2019-05-14 Xencor, Inc. Anticorps dont les points isoelectriques sont modifies
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体

Also Published As

Publication number Publication date
CL2017000053A1 (es) 2017-06-23
AU2015286707B2 (en) 2020-05-21
EP3166970B1 (fr) 2021-03-10
US20160009793A1 (en) 2016-01-14
PE20170768A1 (es) 2017-07-04
CA2951990A1 (fr) 2016-01-14
SI3166970T1 (sl) 2021-09-30
MY184890A (en) 2021-04-29
TW201613964A (en) 2016-04-16
KR20230129449A (ko) 2023-09-08
CN106661103B (zh) 2020-11-03
IL250001B (en) 2021-05-31
SG11201610734RA (en) 2017-01-27
JP6628786B2 (ja) 2020-01-15
AU2015286707A1 (en) 2017-01-12
WO2016005466A2 (fr) 2016-01-14
MX2017000378A (es) 2017-08-25
EP3865510A3 (fr) 2021-10-27
CO2017000346A2 (es) 2017-06-09
KR20170037900A (ko) 2017-04-05
IL282823A (en) 2021-06-30
RU2017103446A3 (fr) 2019-02-26
RS61717B1 (sr) 2021-05-31
WO2016005466A3 (fr) 2016-04-07
CY1124563T1 (el) 2022-07-22
US9573994B2 (en) 2017-02-21
RU2700104C2 (ru) 2019-09-12
KR102564384B1 (ko) 2023-08-07
PT3166970T (pt) 2021-04-26
DK3166970T3 (da) 2021-05-25
SMT202100263T1 (it) 2021-07-12
IL282823B2 (en) 2024-05-01
MA53887A (fr) 2021-10-27
ES2865112T3 (es) 2021-10-15
CN112390881A (zh) 2021-02-23
LT3166970T (lt) 2021-05-10
AU2015286707A8 (en) 2017-01-19
CN112390881B (zh) 2025-02-21
KR102763164B1 (ko) 2025-02-07
HRP20210680T1 (hr) 2021-06-11
PH12017500032B1 (en) 2022-09-02
PL3166970T3 (pl) 2021-09-13
UA121550C2 (uk) 2020-06-25
MX379241B (es) 2025-03-10
AR101130A1 (es) 2016-11-23
CA2951990C (fr) 2023-08-22
TWI678376B (zh) 2019-12-01
ZA201706272B (en) 2019-02-27
RU2017103446A (ru) 2018-08-13
PH12017500032A1 (en) 2017-05-15
IL250001A0 (en) 2017-03-30
EP3166970A2 (fr) 2017-05-17
HUE053809T2 (hu) 2021-07-28
JO3537B1 (ar) 2020-07-05
MA40224B1 (fr) 2021-05-31
CN106661103A (zh) 2017-05-10
EP3865510A2 (fr) 2021-08-18
NZ727338A (en) 2024-08-30
BR112016030774A2 (pt) 2018-01-16
JP2017521427A (ja) 2017-08-03
IL282823B1 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MA40224A (fr) Anticorps se liant aux protofibrilles ass améliorés
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA53937A (fr) Compositions comprenant des souches bactériennes
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA57599B1 (fr) Semaglutide pour le traitement de la démence d'alzheimer
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3470847A3 (fr) Norme de quantification des agrégats pathogènes à partir des protéines endogènes
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
WO2014117680A3 (fr) Utilisation des niveaux d'arn messager du gène trpc6 dans des cellules du sang périphérique pour le dépistage/diagnostic précoce de la démence sénile
WO2014053110A3 (fr) Peptide pour le traitement et le diagnostic précoce de la maladie d'alzheimer et d'autres tauopathies
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
HK1232900A1 (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
MA35580B1 (fr) Composition pharmaceutique
MA41059B1 (fr) Compositions comprenant des souches bactériennes